Acrylamide intake and endometrial cancer risk: a meta-analysis

Background: Some observational studies have indicated that acrylamide intake is associated with of endometrial cancer risk; however, the association was not supported by all published observational studies. This study aimed to assess the relationship between acrylamide intake and endometrial cancer risk. Materials and methods: We conducted a meta-analysis to estimate the association of acrylamide intake with endometrial cancer risk by searching potential studies from PubMed, Medline and Embase through February 2017. The pooled OR and 95% CI of endometrial cancer were computed for the highest versus lowest levels of acrylamide intake. Result: Five observational studies were included into the present meta-analysis. The pooled OR (95% CI) of endometrial cancer for the highest vs. the lowest levels of acrylamide intake was 1.07 (0.94, 1.23). The dose-response analysis showed that the risk of endometrial cancer did not change significantly for every 10 mu g/d increment in acrylamide intake, the pooled OR (95% CI) was 1.01 (0.98, 1.05). In subgroup-analysis, this study found an increased endometrial cancer risk in never-smoking women who consumed high levels of acrylamide intake. However, in the ever smokers, premenopausal or postmenopausal women, and the prospective cohort studies, no significant positive association of acrylamide intake and endometrial cancer risk was found. Conclusion: The present meta-analysis did not support a significant association of acrylamide intake and endometrial cancer risk. however, never-smoking women who consumed high acrylamide had an increased risk of endometrial cancer.